Rock Springs Capital LLC
CIK 1735397 · last filed 2021-10-26
Rock Springs Capital LLC is a corporate insider who has filed 5 SEC Form 4 insider transactions across 5 companies since 2020. The most recent filing, for XLO, was dated Oct 26, 2021. Across all open-market trades the lifetime net is +$111.9M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $7.3M across reported positions. The firm reports its address in Baltimore, MD. 15 SEC filings were submitted jointly with Rock Springs Capital Management LP.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
XLO price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SUITE 1070
BALTIMORE, MD 21202
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| XLO | 10%+ Owner | 54,034 | $7.31 | $395.0K | $32.00M | 1 | 2021-10-26 |
| Verve Therapeutics, Inc. (VERV) Delisted | 10%+ Owner | 152,926 | $11.13 | $1.70M | $21.09M | 1 | 2021-06-22 |
| AVIR | 10%+ Owner | 1,654,724 | $4.16 | $6.88M | $18.00M | 1 | 2020-11-04 |
| Inozyme Pharma, Inc. (INZY) Delisted | 10%+ Owner | 467,884 | $4.00 | $1.87M | $28.80M | 1 | 2020-07-28 |
| Enliven Therapeutics, Inc. (IMRA) Delisted | 10%+ Owner | 68,353 | $14.59 | $997.3K | $12.00M | 1 | 2020-03-16 |
Recent Filings
5 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2021-10-26 | XLO | Mixed | +5,631,064 | $32.00M | EDGAR |
| 2021-06-22 | Verve Therapeutics, Inc. (VERV) Delisted | Mixed | +3,237,672 | $21.09M | EDGAR |
| 2020-11-04 | AVIR | Mixed | +5,833,257 | $18.00M | EDGAR |
| 2020-07-28 | Inozyme Pharma, Inc. (INZY) Delisted | Mixed | +3,203,652 | $28.80M | EDGAR |
| 2020-03-16 | Enliven Therapeutics, Inc. (IMRA) Delisted | Mixed | +1,570,233 | $12.00M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.